AKBLF
Price
$28.20
Change
+$0.55 (+1.99%)
Updated
Jul 2 closing price
Capitalization
6.51B
SMMT
Price
$24.55
Change
+$1.93 (+8.53%)
Updated
Jul 3 closing price
Capitalization
18.23B
32 days until earnings call
Interact to see
Advertisement

AKBLF vs SMMT

Header iconAKBLF vs SMMT Comparison
Open Charts AKBLF vs SMMTBanner chart's image
Alk Abello AS
Price$28.20
Change+$0.55 (+1.99%)
Volume$65
Capitalization6.51B
Summit Therapeutics
Price$24.55
Change+$1.93 (+8.53%)
Volume$12.73M
Capitalization18.23B
AKBLF vs SMMT Comparison Chart in %
Loading...
AKBLF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SMMT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AKBLF vs. SMMT commentary
Jul 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKBLF is a Hold and SMMT is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 05, 2025
Stock price -- (AKBLF: $28.20 vs. SMMT: $24.55)
Brand notoriety: AKBLF and SMMT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKBLF: 934% vs. SMMT: 289%
Market capitalization -- AKBLF: $6.51B vs. SMMT: $18.23B
AKBLF [@Biotechnology] is valued at $6.51B. SMMT’s [@Biotechnology] market capitalization is $18.23B. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKBLF’s FA Score shows that 0 FA rating(s) are green whileSMMT’s FA Score has 1 green FA rating(s).

  • AKBLF’s FA Score: 0 green, 5 red.
  • SMMT’s FA Score: 1 green, 4 red.
According to our system of comparison, both AKBLF and SMMT are a good buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKBLF’s TA Score shows that 3 TA indicator(s) are bullish while SMMT’s TA Score has 4 bullish TA indicator(s).

  • AKBLF’s TA Score: 3 bullish, 2 bearish.
  • SMMT’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, AKBLF is a better buy in the short-term than SMMT.

Price Growth

AKBLF (@Biotechnology) experienced а +1.99% price change this week, while SMMT (@Biotechnology) price change was +15.15% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

SMMT is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SMMT($18.2B) has a higher market cap than AKBLF($6.51B). AKBLF has higher P/E ratio than SMMT: AKBLF (42.64) vs SMMT (26.36). SMMT YTD gains are higher at: 37.574 vs. AKBLF (26.174). AKBLF has higher annual earnings (EBITDA): 1.55B vs. SMMT (-235.08M). AKBLF has more cash in the bank: 517M vs. SMMT (361M). SMMT has less debt than AKBLF: SMMT (6.45M) vs AKBLF (800M). AKBLF has higher revenues than SMMT: AKBLF (5.71B) vs SMMT (0).
AKBLFSMMTAKBLF / SMMT
Capitalization6.51B18.2B36%
EBITDA1.55B-235.08M-660%
Gain YTD26.17437.57470%
P/E Ratio42.6426.36162%
Revenue5.71B0-
Total Cash517M361M143%
Total Debt800M6.45M12,403%
FUNDAMENTALS RATINGS
AKBLF vs SMMT: Fundamental Ratings
AKBLF
SMMT
OUTLOOK RATING
1..100
5035
VALUATION
overvalued / fair valued / undervalued
1..100
82
Overvalued
95
Overvalued
PROFIT vs RISK RATING
1..100
4537
SMR RATING
1..100
4998
PRICE GROWTH RATING
1..100
4236
P/E GROWTH RATING
1..100
849
SEASONALITY SCORE
1..100
4537

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AKBLF's Valuation (82) in the null industry is in the same range as SMMT (95) in the Biotechnology industry. This means that AKBLF’s stock grew similarly to SMMT’s over the last 12 months.

SMMT's Profit vs Risk Rating (37) in the Biotechnology industry is in the same range as AKBLF (45) in the null industry. This means that SMMT’s stock grew similarly to AKBLF’s over the last 12 months.

AKBLF's SMR Rating (49) in the null industry is somewhat better than the same rating for SMMT (98) in the Biotechnology industry. This means that AKBLF’s stock grew somewhat faster than SMMT’s over the last 12 months.

SMMT's Price Growth Rating (36) in the Biotechnology industry is in the same range as AKBLF (42) in the null industry. This means that SMMT’s stock grew similarly to AKBLF’s over the last 12 months.

SMMT's P/E Growth Rating (9) in the Biotechnology industry is significantly better than the same rating for AKBLF (84) in the null industry. This means that SMMT’s stock grew significantly faster than AKBLF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AKBLFSMMT
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
24%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
N/A
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
Bearish Trend 2 days ago
20%
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
34%
Bullish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
34%
Bullish Trend 2 days ago
90%
Advances
ODDS (%)
N/A
Bullish Trend 2 days ago
85%
Declines
ODDS (%)
N/A
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
67%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
37%
Bearish Trend 2 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
AKBLF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SMMT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
TBT35.900.48
+1.36%
ProShares UltraShort 20+ Year Treasury
BLCR36.560.34
+0.95%
iShares Large Cap Core Active ETF
QMNV21.460.07
+0.34%
FT Vest Nasdaq-100® Mod Buffr ETF – Nov
QAT18.56N/A
N/A
iShares MSCI Qatar ETF
BNDW69.02N/A
N/A
Vanguard Total World Bond ETF

AKBLF and

Correlation & Price change

A.I.dvisor tells us that AKBLF and MNPR have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AKBLF and MNPR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKBLF
1D Price
Change %
AKBLF100%
N/A
MNPR - AKBLF
29%
Poorly correlated
+3.10%
MSCLF - AKBLF
27%
Poorly correlated
N/A
IOVA - AKBLF
26%
Poorly correlated
N/A
SMMT - AKBLF
25%
Poorly correlated
+8.53%
VBIZF - AKBLF
24%
Poorly correlated
N/A
More

SMMT and

Correlation & Price change

A.I.dvisor indicates that over the last year, SMMT has been closely correlated with BCDA. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if SMMT jumps, then BCDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SMMT
1D Price
Change %
SMMT100%
+8.53%
BCDA - SMMT
70%
Closely correlated
+1.73%
TIL - SMMT
52%
Loosely correlated
+15.50%
BNTX - SMMT
51%
Loosely correlated
+1.61%
RLAY - SMMT
45%
Loosely correlated
N/A
VBIZF - SMMT
42%
Loosely correlated
N/A
More